Add like
Add dislike
Add to saved papers

FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials.

18 F-fluorodeoxyglucose positron emission tomography integrated with computed tomography (18 F-FDG PET/CT) is an effective modality to assess disease burden, detect extra-medullary disease and monitor minimal residual disease (MRD) for multiple myeloma (MM) patients. This modality of imaging is incorporated in the International Myeloma Working Group (IMWG) response criteria that are widely used in MM clinical trials. Interpretative pitfalls are commonly encountered in 18 F-FDG PET/CT studies and proper interpretation requires knowledge of the normal physiologic distribution of the tracer affecting available 18 F-FDG for tumor tissue uptake. We describe a series of MM patients who exhibited a deep response to treatment, based on clinical features, serum markers and bone marrow (BM) biopsy. However, these patients seemed to have new lesions on post-therapy 18 F-FDG PET/CT images which could be interpreted as progressive disease according to the IMWG criteria. Sequestration phenomenon, which is the disappearance of 18 F-FDG sequestration by myeloma-infiltrated marrow after successful anti-myeloma therapy, could lead to unmasking of new 18 F-FDG-avid lesions on post-therapy PET/CT due to higher 18 F-FDG bioavailability to residual tumor tissue. Clinical correlation, awareness of the 18 F-FDG sequestration in myeloma infiltrated BM and its impact on other 18 F-FDG avid areas in the body are necessary to avoid potential pitfalls in end-of-treatment imaging interpretation. While considering patients for clinical trials, clinicians should be mindful of this sequestration phenomenon in the interpretation of post-therapy PET/CT imaging in MM patients with initially heavily infiltrated marrow.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app